Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EP 101 - EpiThany

Next Previous
Search
Drug Profile

EP 101 - EpiThany

Alternative Names: EP-101 - EpiThany; STEMVAC

Latest Information Update: 18 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiThany; University of Washington
  • Class Antigens; Antineoplastics; DNA vaccines; Vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 13 Jul 2022 University of Washington, University of Wisconsin and National Cancer Institute (NCI) plan a phase II trial for Breast cancer (early-stage disease, Second-line therapy or greater) in the US (IV) in December 2022 (NCT05455658)
  • 16 Feb 2022 University of Washington, United States Department of Defense plans a phase II trial in Non small cell lung cancer (Late-stage disease, Combination therapy) in USA (NCT05242965) (Intradermally)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Breast-cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top